Education
About Us
Working with TipRanks
Follow Us
Kamada (KMDA)
NASDAQ:KMDA
KMDA Stock Chart & Stats
$7.95
$0.85(12.50%)
At close: 4:00 PM EST
$7.95
$0.85(12.50%)
Day’s Range― - ―
52-Week Range$5.54 - $9.16
Previous CloseN/A
Volume680.22K
Average Volume (3M)84.80K
Market Cap
$474.56M
Enterprise Value$1.13B
Total Cash (Recent Filing)$72.00M
Total Debt (Recent Filing)$11.47M
Price to Earnings (P/E)22.4
Beta0.65
Next Earnings
Mar 18, 2026EPS Estimate
0.08Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.09
Shares Outstanding57,681,590
10 Day Avg. Volume55,458
30 Day Avg. Volume84,803
Financial Highlights & Ratios
PEG Ratio0.31
Price to Book (P/B)1.28
Price to Sales (P/S)2.07
P/FCF Ratio9.03
Enterprise Value/Market Cap2.38
Enterprise Value/Revenue6.45
Enterprise Value/Gross Profit14.75
Enterprise Value/Ebitda30.32
Forecast
1Y Price Target
$14.00Price Target Upside76.10% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Biosimilars And DistributionExpansion of the distribution segment combined with planned biosimilar launches should diversify revenue streams and increase the company's addressable market.
Commercial ExpansionBroader penetration of the commercial product portfolio across United States and international markets is expected to drive revenue growth as sales reach new territories.
Vertical IntegrationRamping in-house plasma collection is intended to reduce specialty plasma input costs, strengthen vertical integration, and create a new recurring revenue stream.
Bears Say
Clinical Enrollment RiskTrial enrollment for the inhaled AAT program remains substantially below the reduced sample size, representing an overhang that could delay clinical progress and outcomes.
Drug Development And Capital Allocation RiskDiscontinuation of the Phase 3 inhaled AAT trial creates uncertainty about the drug development pipeline and raises questions about optimal capital redeployment to support growth.
Royalty HeadwindA reduced GLASSIA royalty rate from a partner will pressure product royalty income and could weigh on overall revenue and margins.
Kamada News
KMDA FAQ
What was Kamada’s price range in the past 12 months?
Kamada lowest stock price was $5.54 and its highest was $9.15 in the past 12 months.
What is Kamada’s market cap?
Kamada’s market cap is $474.56M.
When is Kamada’s upcoming earnings report date?
Kamada’s upcoming earnings report date is Mar 18, 2026 which is in 64 days.
How were Kamada’s earnings last quarter?
Kamada released its earnings results on Nov 10, 2025. The company reported $0.092 earnings per share for the quarter, the consensus estimate of $0.092 by $0.
Is Kamada overvalued?
According to Wall Street analysts Kamada’s price is currently Undervalued.
Does Kamada pay dividends?
Kamada pays a Notavailable dividend of $0.2 which represents an annual dividend yield of N/A. See more information on Kamada dividends here
What is Kamada’s EPS estimate?
Kamada’s EPS estimate is 0.08.
How many shares outstanding does Kamada have?
Kamada has 57,681,590 shares outstanding.
What happened to Kamada’s price movement after its last earnings report?
Kamada reported an EPS of $0.092 in its last earnings report, expectations of $0.092. Following the earnings report the stock price went up 5.405%.
Which hedge fund is a major shareholder of Kamada?
Currently, no hedge funds are holding shares in KMDA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Kamada Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$14.00 (76.10% Upside)
$14.00 (76.10% Upside)
Blogger Sentiment
Bullish
KMDA Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 2.9K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 3.0%
Last 30 Days ▼ 3.0%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
11.72%
12-Months-Change
Fundamentals
Return on Equity
7.86%
Trailing 12-Months
Asset Growth
7.40%
Trailing 12-Months
Company Description
Kamada
Kamada Ltd. provides plasma-derived protein therapeutics. It operates in two segments, Proprietary Products and Distribution. The company offers KAMRAB/KEDRAB for prophylaxis of rabies disease; CYTOGAM for prophylaxis of cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplant; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; VARIZIG for post exposure prophylaxis of varicella; and GLASSIA for intravenous AATD. It also provides KamRho (D) IM for prophylaxis of hemolytic disease of newborns; KamRho (D) IV for immune thermobocytopunic purpura; and snake bite antiserum to treat snake bites by the vipera palaestinae and echis coloratus. In addition, the company distributes BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN for Allergic rhinitis and Urticaria; IVIG for immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for hepatitis B; MEGALOTECT CP for cytomegalovirus virus; RUCONEST for angioedema attacks; heparin sodium injection for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. Further, it offers IXIARO for Japanese encephalitis; VIVOTIF for Salmonella Typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis ; and ELIGARD for prostate cancer. The company markets its products through strategic partners in the United States, as well as through distributors internationally. Kamada Ltd. has strategic partnerships with Takeda Pharmaceuticals Company Limited; PARI GmbH; and Kedrion Biopharma. The company was incorporated in 1990 and is headquartered in Rehovot, Israel.
KMDA Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a positive outlook with strong revenue growth, increased EBITDA, and successful product launches. However, challenges remain with declining Glacia royalties, below-plan Cytogam sales, and slow clinical trial enrollment.View all KMDA earnings summariesKMDA Stock 12 Month Forecast
Average Price Target
$14.00
▲(76.10% Upside)
Technical Analysis
Ownership Overview
―
Insiders
0.49% Mutual Funds
2.34% Other Institutional Investors
96.02% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---